TISSIUM is a clinical-stage medtech company developing proprietary biomorphic programmable polymers for atraumatic tissue reconstruction in surgery.[1][7] It builds a platform of fully biosynthetic, elastomeric products including sealants, adhesives, and 3D-printed implants, serving surgeons and patients in cardiovascular, nerve repair, hernia repair, and other procedures to solve persistent challenges in restoring damaged tissue function without sutures or tacks.[2][5][6] With one commercial product (COAPTIUM® CONNECT for sutureless nerve repair, first used commercially in the US in November 2025) and six in development across three verticals, TISSIUM shows strong growth momentum, including 3 CE Marks, 64 granted patents, FDA De Novo Grant, and expansion into manufacturing and global clinical studies.[1][2][6]
The company's integrated platform supports internal programs and partnerships, with offices in Paris, Boston, and a manufacturing site in Roncq, France.[1][3][6]
TISSIUM was founded in 2013 in Paris (initially as Gecko Biomedical) by CEO Christophe Bancel and co-founder Maria Pereira, PhD (now Chief Innovation Officer), leveraging breakthrough polymer research from MIT's Robert Langer and Brigham and Women's Hospital's Jeffrey M. Karp.[1][5][8] The idea emerged from recognizing the polymers' potential—discovered in their US labs—to revolutionize tissue reconstruction, a challenge dating back to early surgery.[1][3]
Early traction included a 2013 Science Translational Medicine publication, first ISO certification, vascular sealant clinical testing, and platform expansion to 3D printing.[1] Pivotal moments: GLP pre-clinical studies completed for nerve (COAPTIUM®) and hernia (ECLIPSIUM) products, nerve clinical study completion, FDA De Novo Grant for COAPTIUM® CONNECT, and pipeline growth to seven products.[1][6]
TISSIUM stands out through its proprietary technology and system-level approach:
TISSIUM rides the medtech trend toward biomaterials and minimally invasive, atraumatic surgery, addressing multi-billion-dollar markets in tissue repair amid rising procedure volumes from aging populations and complex interventions.[2][5] Timing aligns with advances in programmable materials and 3D bioprinting, enabling customizable solutions for unmet needs like high-pressure vascular sealing or peripheral nerve regeneration.[1][7]
Market forces favoring it include demand for sutureless alternatives reducing complications, global medtech partnerships (e.g., Sofinnova), and cross-border expansion (US/Europe/Asia).[2][6] It influences the ecosystem by pioneering biosynthetic polymers from academic IP, fostering co-developments, and setting standards for reconstructive tech in cardiovascular, GI, ENT, and neurosurgery.[1][5]
TISSIUM's momentum—marked by COAPTIUM® CONNECT's US launch—positions it for pipeline commercialization, starting with hernia and cardiovascular products, while expanding to ENT, fistulas, and neurosurgery via partnerships.[6] Trends like AI-driven customization, global regulatory harmonization, and biotech-medtech convergence will accelerate its growth, potentially capturing share in $10B+ repair markets.
Its influence may evolve from innovator to platform leader, enabling broader atraumatic procedures worldwide, building on MIT roots to redefine surgical reconstruction.[1][2] This cements TISSIUM's role in a new era of tissue repair, directly tackling surgery's core challenge.[7]
TISSIUM has raised $149.0M in total across 4 funding rounds.
TISSIUM's investors include Abingworth, Soffinova Partners, Seroba Life Sciences, Karista, Paul Walker.
TISSIUM has raised $149.0M across 4 funding rounds. Most recently, it raised $54.0M Series D in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $54.0M Series D | Abingworth, Soffinova Partners | |
| Aug 1, 2021 | $59.0M Series C | Abingworth, Soffinova Partners | |
| Mar 1, 2016 | $25.0M Series A | Seroba Life Sciences | |
| Dec 1, 2013 | $11.0M Series A | Karista, Paul Walker, Seroba Life Sciences |
